ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,081.55
-0.04%
Dow Jones
42,840.26
1.18%
Gold vs US Dollar
2,629.33
0.20%
Brent Oil
72.98
0.36%
Bitcoin
95,864.56
0.79%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. MoonLake Immunotherapeutics (MLTX)

  7. MoonLake Immunotherapeutics (MLTX) News

MoonLake Immunotherapeut... (MLTX)

MoonLake Immunotherapeutics
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MLTX
DateTimeSourceHeadlineSymbolCompany
18/12/202421:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
13/11/202413:00GlobeNewswire Inc.MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritisNASDAQ:MLTXMoonLake Immunotherapeutics
07/11/202412:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MLTXMoonLake Immunotherapeutics
07/11/202412:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
07/11/202412:00GlobeNewswire Inc.MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:MLTXMoonLake Immunotherapeutics
08/10/202420:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLTXMoonLake Immunotherapeutics
11/09/202411:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
09/09/202411:00GlobeNewswire Inc.MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11NASDAQ:MLTXMoonLake Immunotherapeutics
07/08/202412:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MLTXMoonLake Immunotherapeutics
07/08/202412:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
07/08/202412:00GlobeNewswire Inc.MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11NASDAQ:MLTXMoonLake Immunotherapeutics
10/06/202420:40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
10/06/202412:00GlobeNewswire Inc.MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic ArthritisNASDAQ:MLTXMoonLake Immunotherapeutics
07/06/202421:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLTXMoonLake Immunotherapeutics
07/06/202421:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLTXMoonLake Immunotherapeutics
07/06/202420:59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLTXMoonLake Immunotherapeutics
07/06/202420:58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLTXMoonLake Immunotherapeutics
06/06/202411:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
16/05/202412:00GlobeNewswire Inc.MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativaNASDAQ:MLTXMoonLake Immunotherapeutics
07/05/202412:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MLTXMoonLake Immunotherapeutics
07/05/202412:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
07/05/202412:00GlobeNewswire Inc.MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:MLTXMoonLake Immunotherapeutics
07/05/202411:57Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:MLTXMoonLake Immunotherapeutics
10/04/202411:00Business WireMoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint ConditionsNASDAQ:MLTXMoonLake Immunotherapeutics
10/04/202411:00GlobeNewswire Inc.MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions NASDAQ:MLTXMoonLake Immunotherapeutics
11/03/202412:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MLTXMoonLake Immunotherapeutics
10/03/202416:00GlobeNewswire Inc.MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D DayNASDAQ:MLTXMoonLake Immunotherapeutics
04/03/202413:00GlobeNewswire Inc.MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024NASDAQ:MLTXMoonLake Immunotherapeutics
01/03/202400:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLTXMoonLake Immunotherapeutics
01/03/202400:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MLTXMoonLake Immunotherapeutics
 Showing the most relevant articles for your search:NASDAQ:MLTX

Your Recent History

LSE
SYME
Supply@me Capital
LSE
ITM
Itm Power
LSE
BOO
Boohoo
LSE
AAZ
Anglo Asian Mining
LSE
SEE
Seeing Machines
LSE
POS
Plexus
LSE
DLG
Direct Line Insurance
LSE
GRL
Goldstone Resources
LSE
AV.
Aviva
LSE
WG.
Wood Group (john)
LSE
THG
Thg
LSE
VAST
Vast Resources
LSE
ZPHR
Zephyr Energy
LSE
ITV
Itv
LSE
PFC
Petrofac
LSE
HE1
Helium One Global
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads